{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:13:59Z","timestamp":1793330039500,"version":"4.5.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-002-096"],"award-info":[{"award-number":["113-2314-B-002-096"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH. 110-005105"],"award-info":[{"award-number":["NTUH. 110-005105"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-002-006"],"award-info":[{"award-number":["113-2314-B-002-006"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>ctDNA has been reported as a predictor of the progression of metastatic breast cancer and recurrence in early breast cancer (EBC). This study explored whether ctDNA persistence in patients with HER2-positive (HER2+) EBC who achieved pathologic complete response (pCR) after neoadjuvant therapy (NAT) indicates a poor prognosis and the need for adjuvant T-DM1. Of the 117 patients enrolled, 25 patients achieved pCR after NAT and 92 patients did not. Six of the 25 pCR patients showed positive ctDNA after NAT, whereas 26 of the 92 non-pCR patients were ctDNA-positive. Eighteen patients received adjuvant T-DM1, whereas 99 patients did not. Among the non\u2013T-DM1 group, ctDNA positivity after NAT independently predicted recurrence (HR, 5.505; 95% confidence interval, 1.950\u201315.540; P = 0.001). pCR patients with ctDNA positivity experienced a shorter recurrence-free survival (RFS) compared with pCR and ctDNA-negative patients after NAT(P = 0.008), whereas non-pCR patients with ctDNA-negative tumors had a better RFS compared with non-pCR patients with ctDNA-positive status (P = 0.001). In the 79 patients who were ctDNA-positive before NAT, clearance of ctDNA by NAT was associated with significantly better RFS than nonclearance (P &amp;lt; 0.001). Adjuvant T-DM1 also significantly improved the ctDNA clearance rate (P = 0.035) compared with non\u2013T-DM1 therapy in patients with ctDNA positivity after NAT during serial tests. We classified the 117 patients as T-DM1\/non\u2013T-DM1 and ctDNA-positive\/negative, and a significantly shorter RFS was observed in patients with ctDNA-positive\/non\u2013T-DM1 (P = 0.029) than in the other three patient groups. In conclusion, the presence of ctDNA after NAT in patients with HER2+ EBC is associated with a poor prognosis and may indicate adjuvant T-DM1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Adjuvant T-DM1 can improve the survival of HER2+ EBC patients who don\u2019t achieve pCR. Our study showed that ctDNA positivity after NAT was associated with decreased RFS. ctDNA-positive status after NAT can be switched to ctDNA-negative status in patients treated with T-DM1. Patients who were ctDNA-positive and treated with T-DM1 had a similar RFS to those who were ctDNA-negative, indicating that \u201cctDNA positivity\u201d could be a marker determining adjuvant T-DM1 therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0234","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:01:56Z","timestamp":1768402916000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ctDNA Detected after Neoadjuvant Therapy for HER2-Positive Breast Cancer Is Associated with Inferior Outcomes and May Inform Adjuvant Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-398X","authenticated-orcid":false,"given":"Po-Han","family":"Lin","sequence":"first","affiliation":[{"name":"1Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan."},{"name":"2Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-0138","authenticated-orcid":false,"given":"Li-Wei","family":"Tsai","sequence":"additional","affiliation":[{"name":"3Department of Surgery, National Taiwan University Hospital and Medical College of the National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-9234","authenticated-orcid":false,"given":"Chiao","family":"Lo","sequence":"additional","affiliation":[{"name":"3Department of Surgery, National Taiwan University Hospital and Medical College of the National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-887X","authenticated-orcid":false,"given":"Sung-Hsin","family":"Kuo","sequence":"additional","affiliation":[{"name":"4Department of Oncology, National Taiwan University Hospital and Medical College of the National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3390-561X","authenticated-orcid":false,"given":"Chia-Chun","family":"Ni","sequence":"additional","affiliation":[{"name":"1Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3710-552X","authenticated-orcid":false,"given":"Chih-Hao","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-211X","authenticated-orcid":false,"given":"Chiun-Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Surgery, National Taiwan University Hospital and Medical College of the National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026011410015392900_bib1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026011410015392900_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"2026011410015392900_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026011410015392900_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2026011410015392900_bib6","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","volume":"62","author":"Harbeck","year":"2022","journal-title":"Breast"},{"key":"2026011410015392900_bib7","doi-asserted-by":"crossref","first-page":"860475","DOI":"10.3389\/fonc.2022.860475","article-title":"Markers associated with tumor recurrence in patients with breast cancer achieving a pathologic complete response after neoadjuvant chemotherapy","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"key":"2026011410015392900_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-015-3533-x","article-title":"Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy","volume":"153","author":"Chaudry","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2026011410015392900_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamaoncol.2021.6597","article-title":"Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"2026011410015392900_bib11","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","article-title":"Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance","volume":"22","author":"Stejskal","year":"2023","journal-title":"Mol Cancer"},{"key":"2026011410015392900_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: a review","volume":"126","author":"Cisneros-Villanueva","year":"2022","journal-title":"Br J Cancer"},{"key":"2026011410015392900_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/SLA.0000000000005461","article-title":"Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases","volume":"277","author":"Newhook","year":"2022","journal-title":"Ann Surg"},{"key":"2026011410015392900_bib15","doi-asserted-by":"crossref","first-page":"736769","DOI":"10.3389\/fonc.2021.736769","article-title":"Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"2026011410015392900_bib16","doi-asserted-by":"crossref","first-page":"894861","DOI":"10.3389\/fonc.2022.894861","article-title":"Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"2026011410015392900_bib17","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026011410015392900_bib18","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011410015392900_bib19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"2026011410015392900_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-022-01355-8","article-title":"Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026011410015392900_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","article-title":"The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis","volume":"128","author":"Faulkner","year":"2023","journal-title":"Br J Cancer"},{"key":"2026011410015392900_bib22","doi-asserted-by":"crossref","first-page":"e2026921","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026011410015392900_bib23","doi-asserted-by":"crossref","first-page":"943253","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"2026011410015392900_bib24","doi-asserted-by":"crossref","first-page":"eaax7392","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026011410015392900_bib25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib26","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026011410015392900_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026011410015392900_bib28","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026011410015392900_bib30","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026011410015392900_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026011410015392900_bib32","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/SLA.0000000000005177","article-title":"Potential clinical utility of a targeted circulating tumor DNA Assay in esophageal adenocarcinoma","volume":"276","author":"Cabalag","year":"2022","journal-title":"Ann Surg"},{"key":"2026011410015392900_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026011410015392900_bib34","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/clinchem\/hvac121","article-title":"Circulating tumor DNA as a biomarker for monitoring patients with solid cancers: comparison with standard protein biomarkers","volume":"68","author":"Duffy","year":"2022","journal-title":"Clin Chem"},{"key":"2026011410015392900_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdy552","article-title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","volume":"30","author":"Abbosh","year":"2019","journal-title":"Ann Oncol"},{"key":"2026011410015392900_bib36","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/bjh.15861","article-title":"Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy","volume":"186","author":"Olszewski","year":"2019","journal-title":"Br J Haematol"},{"key":"2026011410015392900_bib37","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1158\/1078-0432.CCR-23-0956","article-title":"Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients","volume":"29","author":"Pascual","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026011410015392900_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/105\/3725266\/crc-24-0234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/1\/105\/3725266\/crc-24-0234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:02:01Z","timestamp":1768402921000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/1\/105\/771732\/ctDNA-Detected-after-Neoadjuvant-Therapy-for-HER2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0234","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}